Virus vectors for highly efficient transgene delivery
US10640785B2 · kind B2 · utility
0Cited by
0References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 21, 2012 |
| Grant date | May 5, 2020 |
| Priority date | — |
| Expiry date | Nov 21, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides viral vector formulations and methods of uses thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. The formulations include a vector and suitable amounts of empty capsids, viral genome-containing capsids, or viral capsid proteins which are optionally chemically or structurally modified and which bind to neutralizing anti-AAV antibodies thereby reducing or preventing antibody-mediated clearance of the vector, but still allowing the genome-containing (therapeutic) vector to transduce target cells and achieve therapeutic gene transfer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.